Strategies for phase II cancer chemoprevention trials: Cervix, endometrium, and ovary

Journal of Cellular Biochemistry

Volumn 59, Issue 23 S, 1995, Pages 1-9

  Kelloff, Gary J ^a   Boone, Charles W ^a   Crowell, James A ^a   Nayfield, Susan G ^a   Hawk, Ernest ^a   Steele, Vernon E ^a   Lubet, Ronald A ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

Cervical cancer; cervical intraepithelial neophsia (CIN); chemoprevention; computer assisted image analysis; endometrial cancer; intermediate biomarkers; ovarian cancer; Phase II trials

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER; ALPHA TOCOPHEROL; ANTIESTROGEN; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; EFLORNITHINE; FENRETINIDE; FOLIC ACID; MEGESTROL; OLTIPRAZ; ORAL CONTRACEPTIVE AGENT; RETINOIC ACID; RETINOID; VIRUS VACCINE;

CHEMISTRY; ENDOMETRIUM TUMOR; FEMALE; HUMAN; OVARY TUMOR; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; REVIEW; UTERINE CERVIX TUMOR; CANCER CONTROL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PLOIDY; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS, PHASE II; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0029445127     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.240590902     Document Type: Article

References (51)

1. Approaches to the development and marketing approval of drugs that prevent cancer
2. Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials
3. Progress in cancer chemoprevention: Perspectives on agent selection and short‐term clinical intervention trials
4. Polyamines as biomarkers of cervical intraepithelial neoplasia
5. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy
6. International Symposium on Polyamines in Cancer. Critical role of polyamines in cancer: Basic mechanisms and clinical approaches
7. The role of vitamins in the etiology of cervical neoplasia: An epidemiological review
8. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all‐ trans‐retinoic acid: A randomized trial
9. Mechanistic considerations in chemopreventive drug development
10. Folate and cancer: A review of the literature
11. Improvment in cervical dysplasia associated with folic acid therapy in users of oral contraceptives
12. Megaloblastic changes in the cervical epithelium. Association with oral contraceptive therapy and reversal with folic acid
13. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial
14. Chemoprevention of cervical cancer with folic acid: A phase III Southwest Oncology Group Intergroup Study
15. Folic acid metabolism and its disruption by pharmacologic agents
16. Epidemiology of uterine cervical cancer
17. Damage to DNA in cervical epithelium related to smoking tobacco
18. Free radicals as targets for cancer chemoprevention: Prospects and problems
19. Genital human papillomavirus infection
20. 53 and human papillomavirus E6 protein in human cervical carcinoma cell lines
21. Human papillomaviruses and cervical neoplasia. II. Intraction of HPV with other factors
22. Tumor suppressor breakdown inhibited in cell cultures
23. Strategy and planning for chemopreventive drug development: Clinical development plans I–tamoxifen
24. Can fenretinide protect women against ovarian cancer?
25. The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers
26. Morphometric and multivariate statistical detection of cancer cells in endometrial cytology
27. A large Kindred with 17q‐linked breast and ovarian cancer: Genetic, phenotypic, and genealogical analysis
28. Breast and ovarian cancer incidence in BRCA1‐mutation carriers
29. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
30. Validation of intermediate endpoints in cancer research
31. Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials
32. Effect of dietary calcium on colonic epithelial‐cell proliferation in subjects at high risk for familial colonic cancer
33. Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium